111 filings
Page 4 of 6
6-K
ry0j 0fon69
9 Oct 20
Current report (foreign)
9:06am
6-K
w7ad9fbkt7d8f8g
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am
6-K
h4up1zm x3
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
6-K
wqv5bsfbqmc 9e98q
21 Sep 20
Current report (foreign)
4:15pm
6-K
paf 672flw5tte
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
dwj317r
11 Sep 20
Current report (foreign)
8:16am
6-K
iyb4s43x7pqk4aaa3lwk
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
hg8mq5hf
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
0su4m5
4 Sep 20
Current report (foreign)
4:01pm
6-K
upamoxcx5up 5t
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
8uvn4eu
13 Aug 20
Current report (foreign)
7:30am
6-K
hcayn
10 Aug 20
Form 6-K for Zai Lab Limited - August 7, 2020
12:00am
6-K
g392u1yp2uc8 9p8
20 Jul 20
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
7:35am
6-K
tg5i1ts
7 Jul 20
Turning Point Therapeutics and Zai Lab Announce
7:35am
6-K
i4f5qmoe4ftur
13 May 20
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
10:22am
6-K
dsrsi9ukvnn 39
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
6-K
idor0yhk0v44gfax
19 Mar 20
Current report (foreign)
7:53am
6-K
dx6jce649tgru
16 Mar 20
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
7:39am
6-K
8d1sffe2xg
27 Jan 20
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
4:41pm
6-K
ro068qgj4 mf
23 Jan 20
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
6:08am